Federated Hermes Inc. Sells 1,123,613 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Federated Hermes Inc. decreased its position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 57.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 823,487 shares of the company’s stock after selling 1,123,613 shares during the quarter. Federated Hermes Inc. owned approximately 1.71% of Amphastar Pharmaceuticals worth $30,576,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the business. Smartleaf Asset Management LLC grew its position in Amphastar Pharmaceuticals by 222.1% during the 4th quarter. Smartleaf Asset Management LLC now owns 715 shares of the company’s stock valued at $26,000 after purchasing an additional 493 shares during the last quarter. Parkside Financial Bank & Trust raised its stake in shares of Amphastar Pharmaceuticals by 806.5% in the fourth quarter. Parkside Financial Bank & Trust now owns 979 shares of the company’s stock worth $36,000 after buying an additional 871 shares during the period. Huntington National Bank boosted its position in shares of Amphastar Pharmaceuticals by 36.9% in the fourth quarter. Huntington National Bank now owns 1,340 shares of the company’s stock worth $50,000 after purchasing an additional 361 shares during the period. TD Private Client Wealth LLC increased its stake in Amphastar Pharmaceuticals by 22.7% in the 4th quarter. TD Private Client Wealth LLC now owns 2,099 shares of the company’s stock worth $78,000 after buying an additional 388 shares in the last quarter. Finally, KBC Group NV raised its stake in Amphastar Pharmaceuticals by 43.1% during the 4th quarter. KBC Group NV now owns 2,159 shares of the company’s stock valued at $80,000 after purchasing an additional 650 shares during the period. Hedge funds and other institutional investors own 65.09% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Piper Sandler reduced their price objective on Amphastar Pharmaceuticals from $36.00 to $32.00 and set a “neutral” rating on the stock in a research note on Friday, March 21st.

Insider Buying and Selling

In other Amphastar Pharmaceuticals news, CFO William J. Peters sold 4,231 shares of the company’s stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $27.54, for a total value of $116,521.74. Following the completion of the transaction, the chief financial officer now owns 97,363 shares in the company, valued at approximately $2,681,377.02. This represents a 4.16 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 27.10% of the stock is currently owned by corporate insiders.

Amphastar Pharmaceuticals Price Performance

Shares of AMPH stock opened at $23.75 on Wednesday. The firm has a market capitalization of $1.13 billion, a price-to-earnings ratio of 7.92, a PEG ratio of 2.19 and a beta of 0.79. Amphastar Pharmaceuticals, Inc. has a fifty-two week low of $22.84 and a fifty-two week high of $53.96. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.61 and a current ratio of 3.43. The stock’s 50-day simple moving average is $29.47 and its 200-day simple moving average is $38.71.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.